Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 525,504,175 mg/tablet - praziquantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 525,504,175 mg/tablet - praziquantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 525,504,175 mg/tablet - praziquantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 150,144,50 mg/tablet - febantel, combinations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

vetoquinol sa - febantel; pyrantel embonate ; praziquantel - tablet - 525,504,175 mg/tablet - praziquantel, combinations

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - hydrochlorothiazide, quantity: 12.5 mg; eprosartan mesilate, quantity: 735.8 mg (equivalent: eprosartan, qty 600 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - teveten plus is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - chlortalidone, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; iron oxide red; colloidal anhydrous silica; lactose monohydrate; maize starch; magnesium stearate - indications as at 19 november 1996: essential arterial hypertension, as long as creatinine clearance is >30 ml/min; as primary therapy or in combination with other antihypertensive agents; stable, chronic heart failure of mild to moderate degree (functional class ii, iii), as long as creatinine clearance is >30ml/min; ascites due to cirrhosis of the liver in stable patients under close control.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.